Continuous Infusion Versus Intermittent Bolus Injection of Rocuronium

Comparison of Hourly Rocuronium Consumption Using Continuous Infusion Versus Intermittent Bolus Injection: a Randomized Controlled Trial

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03060707

Acronym

RCVB

Enrollment

Registered

2017-02-23

Start date

2017-03-23

Completion date

2018-03-31

Last updated

2017-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Muscle Relaxation

Brief summary

The research is to find out whether continuous infusion of rocuronium requires more or less amount of rocuronium, per kilogram and per hour, than bolus administered rocuronium during noncardiac surgery.

Detailed description

comparing the total dose of rocuronium between continuous infusion and intermittent injection

Interventions

DRUGRocuronium Bromide

Continuously infuse, or bolus administer rocuronium.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

2 Years to 12 Years

Healthy volunteers

Inclusion criteria

* Pediatric patients aged between 2 and 12, undergoing elective noncardiac surgery which requires general anesthesia but does not require intense block, and estimated time of surgery is between 2 and 5 hours

Exclusion criteria

* ASA class 3-6 * BMI \>= 30 * Previous history of hepatic failure, renal failure or neuromuscular disease * Patients taking medicine which interacts with rocuronium bromide, before or during surgery: aminoglycosides, lincosamides, acylamino-penicillin antibiotics, tetracyclines, metronidazole (high dose), diuretics, MAO inhibitors, calcium channel blockers, corticosteroids, phenytoin, carbamazepine, or norepinephrine * Previous history of allergic reaction (including anaphylactic reaction) and/or malignant hyperthermia during general anesthesia * Patients taking medicines which contains magnesium

Design outcomes

Primary

Measure	Time frame	Description
Rocuronium dose per kilogram per hour	end of the surgery	Total dose of rocuronium injected during surgery, divided by patient body weight and anesthesia time.

Secondary

Measure	Time frame	Description
Desaturation event	Right after the patient is transferred to the ward, from PACU (1 day)	Whether the participant's peripheral oxygen saturation (SpO2) decreased less than 93%, in postanesthesia care unit (PACU).
Surgical rating scale	end of the surgery	Numerical scale describing how easy it is for surgeon to access surgical field, ranging from1 to 5

Countries

South Korea

Contacts

Primary ContactHee-Soo Kim, Prof.

dami0605@snu.ac.kr+82 02-2072-3659

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026